INVESTMENT OPPORTUNITIES
IDB 01 – non confidential
Natural Psoriasis cream opportunity
Innovative Drugs Regulatory Europe (IDRE) introduces with the DB01, a natural psoriasis cream offering a safer, more effective solution for millions of psoriasis sufferers. Formulated with a unique Neem Tree extract, IDB01 demonstrates strong anti-inflammatory properties with no adverse side effects. This breakthrough cream addresses a pressing need in the $47.24 billion global psoriasis market, offering a natural, well-tolerated alternative to current treatments. With short-term revenue potential from dermatologists and long-term prescription opportunities, IDRE is poised to revolutionize psoriasis care and enhance patients’ quality of life.
IDC 11 – non confidential
Five high tech new transdermal patches
The IDC11 transdermal patch platform, developed by Innovative Drugs Regulatory Europe (IDRE), offers a cutting-edge solution in drug delivery by leveraging recently off-patent generic active ingredients. With five novel patches targeting chronic conditions like back pain, migraine, and viral infections, the platform promises first-to-market opportunities, ease of use, and enhanced patient compliance. Backed by robust intellectual property and a scalable business model, IDRE is set to capture a share of the growing transdermal market, projected to reach $10.97 billion by 2031. IDC11 is primed for rapid commercialization with NDA submissions within two years.
Let's be successful together
If you are considering the possibility of a collaboration or are in charge of a project in which you would like us to support you with our expertise, please do not hesitate to contact us. We will get back to you as soon as possible.